Undercarboxylated Matrix GLA Protein Levels Are Decreased in Dialysis Patients and Related to Parameters of Calcium-phosphate Metabolism and Aortic Augmentation Index
Overview
Authors
Affiliations
Background: Vascular calcifications are related to cardiovascular mortality and morbidity in dialysis patients. Limited data exist on the role of calcification inhibitors, such as matrix-carboxyglutamic acid protein (MGP) in dialysis patients.
Methods: In 120 dialysis patients and 41 age-matched healthy controls, circulating undercarboxylated (uc) MGP levels were measured with a novel ELISA-based competitive assay. The association between ucMGP levels and determinants of bone mineral metabolism, including the calcification inhibitor fetuin-A, was studied. Moreover, the relation between ucMGP levels and arterial stiffness was investigated.
Results: The ucMGP level was significantly lower in dialysis patients compared to controls (173 +/- 70 vs. 424 +/- 126 nmol/l; p < 0.0001). After adjustment for age, sex and duration of dialysis an independent negative association between time-averaged phosphate levels [regression coefficient beta with 95% confidence interval = -64 (-107 to -21)] and a positive association between serum ucMGP and fetuin-A [131 (55-208)] was observed. Duration of dialysis was inversely correlated with ucMGP (r = -0.24, p = 0.007). ucMGP levels were not related to high-sensitivity C-reactive protein or time-averaged calcium levels. After adjustment for age, sex, cardiovascular disease, diabetes, height and mean arterial pressure, ucMGP level was negatively associated with the aortic augmentation index [-0.036 (-0.061 to -0.010)] but not with pulse wave velocity or pulse pressure.
Conclusion: Significantly lower serum ucMGP levels were observed in dialysis patients compared to healthy controls. ucMGP levels were inversely associated with phosphate and positively associated with serum fetuin-A levels. Furthermore, ucMGP levels were inversely associated with the aortic augmentation index. These data suggest that low ucMGP levels may be a marker of active calcification.
Extrahepatic Vitamin K-Dependent Gla-Proteins-Potential Cardiometabolic Biomarkers.
Galunska B, Yotov Y, Nikolova M, Angelov A Int J Mol Sci. 2024; 25(6).
PMID: 38542487 PMC: 10971439. DOI: 10.3390/ijms25063517.
Roumeliotis S, Duni A, Vaios V, Kitsos A, Liakopoulos V, Dounousi E Nutrients. 2022; 14(5).
PMID: 35267901 PMC: 8912443. DOI: 10.3390/nu14050925.
The Role of Vitamin K in CKD-MBD.
Fusaro M, Tondolo F, Gasperoni L, Tripepi G, Plebani M, Zaninotto M Curr Osteoporos Rep. 2022; 20(1):65-77.
PMID: 35132525 PMC: 8821802. DOI: 10.1007/s11914-022-00716-z.
Vitamin K-a neglected player in cardiovascular health: a narrative review.
Hariri E, Kassis N, Iskandar J, Schurgers L, Saad A, Abdelfattah O Open Heart. 2021; 8(2).
PMID: 34785587 PMC: 8596038. DOI: 10.1136/openhrt-2021-001715.
Current Therapy in CKD Patients Can Affect Vitamin K Status.
Cozzolino M, Cianciolo G, Podesta M, Ciceri P, Galassi A, Gasperoni L Nutrients. 2020; 12(6).
PMID: 32486167 PMC: 7352600. DOI: 10.3390/nu12061609.